LOS ANGELES, CA - HeartBeam (NASDAQ: BEAT) has launched a new pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia, a condition characterized by inadequate blood flow and oxygen supply to tissue. The study marks a significant step in the development of the HeartBeam patch, which has the potential to disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.
Coronary artery disease remains one of the most urgent and widespread health threats worldwide, contributing to millions of deaths each year and often progressing silently until a major cardiac event occurs. As healthcare providers search for faster and more accessible ways to identify high-risk patients earlier, HeartBeam's technology aims to provide clinical-grade insights over an extended period, which has not been possible with patch-based ambulatory monitors.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could significantly improve early detection and monitoring of cardiac conditions.”
The pilot study will focus on testing the patch's ability to detect coronary artery disease and ischemia, which are critical for preventing major cardiac events. The implications of this announcement are substantial: if successful, the HeartBeam patch could offer a non-invasive, convenient, and continuous monitoring solution that provides on-demand, clinical-grade ECG data, potentially reducing the need for more invasive procedures and improving patient outcomes.
HeartBeam's technology addresses a significant gap in current ambulatory monitoring, where traditional patches lack the capability to detect ischemia. By enabling on-demand 12-lead ECG generation, the patch could provide physicians with valuable data to make timely decisions, especially for patients with known or suspected coronary artery disease. The market for continuous monitoring and MCT is growing, driven by an aging population and increasing prevalence of cardiovascular risk factors.
The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to BEAT can be found in the company's newsroom at https://ibn.fm/BEAT.
